PCSK9’s involvement in the development and metastasis of lung and liver melanomas, through LDLR or other mechanisms [34, 35], underscores the potential of PCSK9 inhibitors in reducing melanoma risk and improving prognosis. This evidence concerns the gene LDLR and melanoma.